EP0567391A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
A biodegradable tgf-beta delivery system for bone regeneration
Assignee: Bristol Myers Squibb Co
•
Filing: 1993-04-20
•
Granted: —
•
Expires: 2013-04-20
Abstract
Abstract A biodedegradable composition for the con- troled release of TGF-β is described. This composition is very useful for the delivery of TGF-β in the regeneration of bone. The composition contains, among other components, demineralized bone matrix and a degradable homopolymer or copolymer such as poly (lactic-co-glycolic acid). An implantable delivery system for TGF-β release in a predictable and controlled manner with time is described in which an implantable support is formed or coated with this biodegradable composition. TGF-β is stabilized in a composition contains an organic acid buffer, and to which additional components such as mannitol, human serum albumin, gelatin and/or a non-ionic detergent have been added.
Inventors
- 👤 Gombotz Wayne
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 05:15
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/227; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61L27/18; A61P; A61P3/00
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
43 words
A biodegradable composition for the delivery of TGF-β comprising a mixture of demineralized bone matrix and a degradable homopolymer or copolymer, in which said TGF-β is dissolved or dispersed, and which is capable of a predictable and controlled release of TGF-β with time.
Claim 2
Dependent Claim
43 words
A biodegradable composition for the delivery of TGF-β comprising a mixture of demineralized bone matrix and a degradable homopolymer or copolymer, in which said TGF-β is dissolved or dispersed, and which is capable of a predictable and controlled release of TGF-β with time.
Claim 3
Dependent Claim
15 words
The composition according to Claim 1 in which TGF-β is released in a bioactive form.
Claim 4
Dependent Claim
50 words
The composition according to Claim 1 wherein the degradable homopolymers or copolymers is selected from the group consisting of poly (lactic acid), poly (lactic-co-glycolic acid), poly (glycolic acid), poly (caprolactone), poly (hydroxybutyric acid), poly (anhydrides), poly (ortho esters), poly (carbonates), poly (amides), poly (acetals), poly (amino acids) and poly (cyanocrylates).
Claim 5
Dependent Claim
13 words
The composition according to Claim 1, wherein said TGF-β is TGF-β 1 .
Claim 6
Dependent Claim
11 words
The composition according to Claim 1, wherein said TGF-β is TGf-513.
Claim 7
Dependent Claim
13 words
The composition according to Claim 1, wherein said TGF-β is bone morphogenetic protein.
Claim 8
Dependent Claim
28 words
The composition according to Claim 1, where said mixture further comprises an additive which acts as a plasticizer or modifies the release kinetics of TGF-β from said composition.
Claim 9
Dependent Claim
12 words
The composition according to Claim 7, wherein said additive is an oligo-L-lactide.
Claim 10
Dependent Claim
11 words
The composition according to Claim 7, wherein said additive is collagen.
Claim 11
Dependent Claim
11 words
The composition according to Claim 7, wherein said additive is glycerol.
Claim 12
Dependent Claim
47 words
The delivery system for TGF-β comprising an implantable support coated with a biodegradable composition comprising a mixture of demineralized bone matrix and poly (lactic-co-glycolic acid) in which said TGF-ß is dissolved or dispersed, and which is capable of a predictable and controlled release of TGF-β with time.
Claim 13
Dependent Claim
47 words
The delivery system for TGF-β comprising an implantable support coated with a biodegradable composition comprising a mixture of demineralized bone matrix and poly (lactic-co-glycolic acid) in which said TGF-ß is dissolved or dispersed, and which is capable of a predictable and controlled release of TGF-β with time.
Claim 14
Dependent Claim
14 words
The delivery system according to Claim 11, wherein said support is a biodegradable support.
Claim 15
Dependent Claim
15 words
The delivery system according to Claim 11, wherein said support is a non-degradable solid support.
Claim 16
Dependent Claim
25 words
The delivery system according to Claim 11, wherein said system comprises said biodegradable composition formed into an implantable support by solvent casting or compression molding.
Claim 17
Dependent Claim
22 words
A composition for stabilizing TGF-β comprising about 10 to about 50 mM of an organic acid buffer maintained at about pH 2.5
Claim 18
Dependent Claim
22 words
A composition for stabilizing TGF-β comprising about 10 to about 50 mM of an organic acid buffer maintained at about pH 2.5
Claim 19
Dependent Claim
14 words
The composition according to Claim 15, wherein the buffer is a citric acid buffer.
Claim 20
Dependent Claim
14 words
The composition according to Claim 15, wherein the buffer is an acetic acid buffer.
Claim 21
Dependent Claim
30 words
The composition according to Claim 15, wherein the composition contains at least one additional component selected from the group consisting of mannitol, human serum albumin, gelatin and a nonionic detergent.
Claim 22
Dependent Claim
16 words
The composition according to Claim 15, wherein said composition is a lyophilized formulation capable of reconstruction.
References Cited (Backward Citations)
US4563489A
Cited
US4637931A
Cited
WO1989004646A1
Cited
EP0361896A2
Cited
EP0419275A1
Cited
WO1992013565A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.